Group 1 - The Hong Kong Innovation Drug ETF (159570) has seen a significant inflow of funds, with a recent trading volume exceeding 5 billion yuan and a net inflow of over 300 million yuan in the past five days [1] - As of January 20, the total size of the Hong Kong Innovation Drug ETF reached over 25.3 billion yuan, leading the market in terms of scale among innovation drug ETFs [1] - The index components of the ETF showed mixed performance, with notable gains from companies like Kingsoft Biotech and China Biologic Products, while companies like CanSino Biologics experienced declines [3][4] Group 2 - At the J.P. Morgan Healthcare Conference, several Chinese pharmaceutical companies showcased their advancements, including BeiGene's new drug approval in China and plans for accelerated approval in the U.S. [5] - Innovent Biologics and Pfizer are set to conduct five global Phase III trials for their drug SSGJ-707 by 2026, targeting various cancers [6] - The collaboration between NVIDIA and Eli Lilly aims to establish an AI innovation lab with a projected investment of up to 1 billion USD over five years, potentially transforming drug development processes [8] Group 3 - Tempus AI reported a revenue of approximately 1.27 billion USD for 2025, marking an 83% year-on-year increase, driven by significant growth in its diagnostic business [9] - The top ten components of the Hong Kong Innovation Drug ETF account for over 73% of its weight, highlighting the concentration of leading innovative drug companies within the ETF [10]
JPM收官，中国创新药加速全球化！港股通创新药ETF(159570)探底回升翻红，近5日净流入超3亿元，在全市场创新药ETF中规模领跑！
Xin Lang Cai Jing·2026-01-21 02:41